Pepticom, a Jerusalem, Israel-based AI-driven peptide-based therapeutics company, raised its $6.6m Series A1 funding.
The round was led by Japan Israel High Tech Ventures 2 LP with participation from existing investors.
Led by CEO Immanuel Lerner, Pepticom is a biotech company specializing in the AI-driven discovery of peptide-based therapeutics. The company’s mission is to transform medicine by developing targeted, more effective treatments for serious diseases, including autoimmune disorders, and other high-need therapeutic areas. By harnessing the properties of peptides, Pepticom’s innovative approach creates precision therapies that address complex biological challenges, offering a new frontier in drug development
The company intends to use the funds to accelerate the development of its oral IL-17 inhibitor program, targeting improved treatments for autoimmune diseases. This includes the design of two families of fully synthetic, small cyclic peptidomimetic inhibitors with nanomolar activity that target both IL-17A and IL-17F isoforms. Composed of non-natural amino acids, these compounds have achieved key milestones in record time and cost, demonstrating increased stability and extended half-life in vitro and in vivo.
FinSMEs
07/01/2025